Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies

Journal of Neuroscience Research

Volumn 69, Issue 5, 2002, Pages 567-577

  Kirkitadze, Marina D ^a,b   Bitan, Gal ^a,b   Teplow, David B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ADDLs; Amyloid protein; Neurodegeneration; Neurotoxicity; Oligomers; Protein assembly; Protein folding; Protofibrils

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN BLOOD VESSEL; DEGENERATIVE DISEASE; FAMILIAL BRITISH DEMENTIA; HUMAN; NERVE CELL CULTURE; NEUROPATHOLOGY; NEUROPIL; NEUROTOXICITY; OLIGOMERIZATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; METABOLISM; MOUSE; PROTEIN PROCESSING; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMAL; HUMAN; MICE; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS;

EID: 0036708168     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10328     Document Type: Review

References (155)

1. Über einen eigenartigen schweren erkrankungsprozeß der hirnrinde
2. Über eine eigenartige erkrankung der hirnrinde
3. A peculiar form of peripheral neuropathy: Familial atypical generalized amyloidosis with special involvement of the peripheral nerves
4. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
5. Self-assembly of recombinant prion protein of 106 residues
6. β-rich oligomers are not on the pathway to amyloid formation by the prion protein in vitro
7. The genetics of Alzheimer's disease - Current status and future prospects
8. In situ atomic force microscopy study of β-amyloid fibrillization
9. Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å
10. Amyotrophic lateral sclerosis - Recent insights from genetics and transgenic mice
11. The central nervous system in motor neurone disease
12. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1
13. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
14. Impairment of hippocampal long-term potentiation by Alzheimer's amyloid β-peptides
15. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice
16. Transgenic mice with Alzheimer's presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation
17. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS
18. Electron microscopic observation on a fibrous component in amyloid of diverse origins
19. Pathologic conformations of prion proteins
20. Familial amyloid polyneuropathy: An electron microscope study of the peripheral nerve in five cases. I. Interstitial changes
21. Familial amyloid polyneuropathy: An electron microscope study of the peripheral nerve in five cases. II. Nerve fibre changes
22. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease
23. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
24. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy
25. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
26. Review: TTR amyloidosis - Structural features leading to protein aggregation and their implications on therapeutic strategies
27. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
28. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase
29. Immunizations reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
30. Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein
31. Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible
32. Nitrotyrosination contributes minimally to toxicity of mutant SOD1 associated with ALS
33. Progress in the modeling of neurodegenerative diseases in transgenic mice
34. Conformation and toxicity of the ABri peptide in familial British dementia
35. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils
36. Effect of the disulfide bridge and the C-terminal extension on the oligomerization of the amyloid peptide ABri implicated in familial British dementia
37. The neuropathology of Alzheimer's disease
38. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase
39. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis
40. Prion protein (PrP) with aminoproximal deletions restoring susceptibility of PrP knockout mice to scrapie
41. Apoptosis-mediated neurotoxicity induced by β-amyloid and PrP fragments
42. Alzheimer's-type neuropathology in transgenic mice overexpressing VT17F β-amyloid precursor protein
43. Systemic amyloid deposits in familial British dementia
44. Nonfibrillar Aβ toxins in AD: Presence of ADDLs and ADDL-binding proteins in Alzheimer's disease brains
45. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils
46. Congophilic angiopathy of the brain: A clinical and pathological report on two siblings
47. Protofibrils, the unifying toxic molecule of neurodegenerative disorders?
48. Transthyretin: A review from a structural perspective
49. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7 Å resolution
50. The Alzheimer family of diseases - Many etiologies, one pathogenesis
51. Alzheimer's disease: The amyloid cascade hypothesis
52. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy
53. Assembly of Aβ amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease
54. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
55. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial ALS
56. Aggregation state and neurotoxic properties of Alzheimer's β-amyloid peptide
57. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
58. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
59. A new clinical scale for the staging of dementia
60. Amyotrophic lateral sclerosis - Current issues in classification, pathogenesis, and molecular pathology
61. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform
62. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis
63. Diagnosis of Alzheimer's disease
64. Alzheimer's disease - An electron microscopical study
65. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia
66. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis
67. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?
68. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques
69. Aggresomes, inclusion bodies and protein aggregation
70. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
71. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation
72. Aggregation of amyloid β-protein and its neurotoxicity: Enhancement by aluminum and other metals
73. 1-42 are potent central nervous system neurotoxins
74. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice
75. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: Implications for wild-type, V30M, and L55P amyloid fibril formation
76. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions
77. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
78. Paralysis agitans. Pathologische anatomie
79. Solution structure of Syrian hamster prion protein rPrP(90-231)
80. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis
81. Isolation of isoforms of mouse prion protein with PrPSC-like structural properties
82. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease
83. Tau in Alzheimer's disease
84. Neurotoxicity induced by oligomeric versus fibrillar Aβ1-42
85. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
86. Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein
87. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease
88. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
89. Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles
90. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
91. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
92. The transthyretin-retinol-binding protein complex
93. The Clinical Dementia Rating (CDR): Current version and scoring rules
94. High-level neuronal expression of Aβ(1-42) in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
95. Familial adult motor neuron disease: Amyotrophic lateral sclerosis
96. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation
97. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
98. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
99. 1-42 fibrillogenesis
100. 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress
101. Amyloid immunization in Alzheimer's disease: Do we promote amyloid scavenging at the cost of inflammatory degeneration?
102. Peripheral marker of Alzheimer's disease
103. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state
104. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity
105. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy
106. Mutation in the α-synuclein gene identified in families with Parkinson's disease
107. Molecular mapping of Alzheimer's-type dementia in Down's syndrome
108. The prion diseases
109. Shattuck lecture - Neurodegenerative diseases and prions
110. Tau is essential to β-amyloid-induced neurotoxicity
111. NMR structure of the mouse prion protein domain PrP(121-321)
112. Familial ALS-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase
113. β-amyloid from Alzheimer's disease brains inhibits sprouting and survival of sympathetic neurons
114. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
115. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
116. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease
117. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: A clinicopathologic study
118. Evidence against the generation of free hydroxyl radicals from the interaction of copper,zinc-superoxide dismutase and hydrogen peroxide
119. β-peptide immunization: A possible new treatment for Alzheimer's disease
120. The molecular pathology of Alzheimer's disease
121. Alzheimer's disease: A central role for amyloid
122. Alzheimer's disease: Genes, proteins, and therapy
123. Alzheimer's amyloid fibrils: Structure and assembly
124. α-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins
125. The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides
126. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death
127. 2
128. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates
129. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
130. Heredopathia ophthalmo-oto-encephalica
131. Cataract, deafness, cerebral ataxia, psychosis and dementia: A new syndrome
132. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading
133. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice
134. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
135. Structural and kinetic features of amyloid β-protein fibrillogenesis
136. An honorable compromise regarding amyloid in Alzheimer's disease
137. Ultrastructural studies in Alzheimer's presenile dementia
138. A stop-codon mutation in the BRI gene associated with familial British dementia
139. A decamer duplication in the 3′ region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred
140. Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease
141. Amyloid β-protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates
142. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
143. Amyloid β-protein fibrillogenesis: Detection of a protofibrillar intermediate
144. Soluble oligomers of β amyloid(1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus
145. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging
146. Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo
147. Fibril in senile systemic amyloidosis is derived from normal transthyretin
148. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
149. α-synuclein fibrillogenesis is nucleation-dependent: Implications for the pathogenesis of Parkinson's disease
150. Familial presenile dementia with spastic paralysis
151. m value
152. m for hydrogen peroxide
153. NMR solution structure of the human prion protein